Company Overview of MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the company to generate product candidates and enter into various strategic collaborations with global pharmaceutical and biotechnology companies. Its product candidates include Margetuximab, a monoclonal antibody that targets human ep...
9640 Medical Center Drive
Rockville, MD 20850
Founded in 2000
Key Executives for MacroGenics, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $466.5K
Chief Financial Officer, Senior Vice President and Corporate Secretary
Total Annual Compensation: $313.8K
Senior Vice President of Research
Total Annual Compensation: $328.0K
Senior Vice President and General Counsel
Total Annual Compensation: $228.9K
Senior Vice President of Clinical Development
Total Annual Compensation: $148.6K
Compensation as of Fiscal Year 2014.
MacroGenics, Inc. Key Developments
MacroGenics, Inc. Presents Pre-Clinical Data on its Multivalent DR5 DART at the American Association for Cancer Research Annual Meeting
Apr 20 15
MacroGenics, Inc. announced the presentation of pre-clinical data for Dual-Affinity Re-Targeting (DART) molecules that target DR5 at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA. In addition, MacroGenics' collaboration partner, Pfizer Inc., presented pre-clinical data on a DART molecule that simultaneously targets P-cadherin and CD3. Ligation of DR5 with its cognate ligand TRAIL or agonistic monoclonal antibodies elicits a pro-apoptotic signal on cancer cells, leading to programmed cell death. DR5 monoclonal antibodies selected from MacroGenics' discovery platform based on favorable normal/tumor binding properties were incorporated into multivalent DARTs. The efficacy of the DR5 DART molecules in mediating cancer cell cytotoxicity is 10-100 fold enhanced compared to that of TRAIL and previously described agonistic DR5-targeted monoclonal antibodies. Based on their enhanced potency and selectivity, DR5-targeting DARTs represent a new class of therapeutics that may overcome limitations of existing DR5-targeted therapeutics. The pre-clinical data support the use of DR5-engaging DARTs to exploit this apoptotic pathway in multiple cancer types.
MacroGenics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:00 AM
Mar 25 15
MacroGenics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Scott Koenig, Chief Executive Officer, President and Director.
MacroGenics Begins Phase 1 Study of MGD010 for Treatment of Autoimmune Disorders
Mar 16 15
MacroGenics has begun its Phase 1 study with MGD010, the company's first Dual-Affinity Re-Targeting molecule being developed for patients with autoimmune disorders. This Phase 1 clinical trial is a first-in-human, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MGD010 in healthy subjects. MGD010 is a bi-specific molecule that simultaneously targets CD32B and CD79B, two B-cell surface proteins, for the treatment of autoimmune disorders. MGD010 is designed to inhibit B-cell activation by exploiting the inhibitory function of CD32B, a checkpoint molecule expressed by B cells.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 19, 2014